Gillian McGovern, Assistant Editor

The approval comes after clinical trial results in which vanzacaftor/tezacaftor/deutivacaftor (Alyftrek; Vertex Pharmaceuticals) demonstrated superiority compared with elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta; Vertex Pharmaceuticals).

The approval follows positive results from the V005 (NCT03005418) clinical trial.

The findings show a need for researchers and health care professionals to consider model designs to minimize disparities when diagnosing perinatal mood and anxiety disorders (PMADs).

The indication is for patients with locally advanced or metastatic disease who have not previously received treatment with an ALK-inhibitor.

These findings indicate that asthma and allergic rhinitis may be commonly linked, emphasizing the need to identify underlying causes.

If approved, cyclobenzaprine hydrochloride (HCl) will be the first member of a new class of analgesic drugs for fibromyalgia.

The investigators also find that age of initiation and frequent use were not associated with a greater age-related cognitive decline.

The authors note that routine screening in patients with primary ciliary dyskinesia to help identify undiagnosed asthma.

The indication is for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or radiation.

Despite the overall decline in medication non-adherence, adult patients with asthma are continuing to report taking less or skipping doses and refilling prescriptions later to save money.

The treatments are currently undergoing evaluation in the SOLSTICE trial (NCT05461170).

Improvements were observed regardless of whether patients initiated ruxolitinib in the second or third line of treatment.

The pumps can now be used to treat pediatric patients who have symptomatic acute decompensated heart failure and cardiogenic shock.

Compared with placebo, patients with relapsed/refractory (R/R) follicular lymphoma (FL) who were treated with tafasitamab showed a median progression-free survival (PFS) of 22.4 months.

Currently, the treatment is undergoing evaluation in a phase 2a trial.

This update follows May 2021 guidelines which recommended patients with primary biliary cholangitis (PBC) with advanced cirrhosis discontinue obeticholic acid.

Compared prednisolone alone, benralizumab with and without prednisolone resulted in fewer treatment failures and stronger VAS scores.

Patients with chronic graft-versus-host disease (cGVHD) were most likely to receive belumosudil in the fourth line (33.7%) setting or the fifth through seventh line (33.1%).

The combination vaccine candidates will be evaluated in 2 separate phase 1/2 clinical trials.

PLT012 demonstrates its potential against multiple tumors with unmet medical needs.

Two studies found a 2-bag regimen of N-acetylcysteine (NAC) resulted in fewer and shorter delays in treatment as well as decreases in cutaneous non-allergic anaphylactoid reactions.

This builds off prior data that showed safety and efficacy of CD19 and CD22 chimeric antigen receptor (CAR)-T cell therapy in children with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL).

If approved, the treatment will be the first and only once-daily, oral selective somatostatin receptor type 2 nonpeptide agonist available for acromegaly.

In newly diagnosed average and high standard risk B-cell acute lymphoblastic leukemia (B-ALL), blinatumomab improved disease-free survival (DFS) by approximately 97.5% and 94.1%, respectively.

The US Department of Agriculture’s (USDA) guidance will help expedite H5N1 bird flu surveillance within the nation’s milk supply and dairy herds.

The authors found high exposure to butylparaben and low exposure to 4-nonylphenol during pregnancy were risk factors for asthma development in children at 4 years of age.

Children born moderate to late preterm also showed more behavior difficulties compared with those born early term or later.

The authors suggest that targeted interventions to mitigate financial toxicity should be implemented to better support patients.

The indication is for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemotherapy and radiation therapy.

Sacituzumab tirumotecan (sac-TMT; Kelun Pharmaceutical, Merck) is currently being studied to treat non-small cell lung cancer (NSCLC) in the TroFuse-004 and TroFuse-009 trials.